← Leaderboards
Carol H Miao
Seattle Children'S Hospital
$27,105,989
Attributed
$28,187,950
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,102,059 · 15
By mechanism
R01$19,593,114 · 7
U54$11,120,890 · 4
R33$2,457,513 · 1
R21$1,445,542 · 2
R56$485,000 · 1
Top collaborators
- Weidong Xiao11 shared
- Lei Li10 shared
- Peng George Wang1 shared
Most similar at Seattle Children'S Hospital
Same institution · by research overlap
- Lakshmi Rajagopal$23,879,900
- Steven F Ziegler$41,989,753
- Phillip I Tarr$24,056,161
- Donald L Sodora$27,419,798
- D. Noah Sather$18,678,273
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyHemophilia ACellsGene ExpressionMediatingImmune ResponseFactor ViiiGenesProteinsCostAntibodiesPhenotypeGene TransferVariantImmune ToleranceImmunoregulationF8 GenePlasmidsCanis FamiliarisTherapeutic EffectPatternEnzyme Replacement TherapyBypassComplication
Grant awards (58)
Gene Editing for Hemophilia A Treatment Using Lipid Nanoparticles$734,329
R01 · FY2025 · HL · contact PI
Gene Editing for Hemophilia A Treatment Using Lipid Nanoparticles$758,254
R01 · FY2024 · HL · contact PI
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$667,660
R01 · FY2024 · HL · contact PI
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia A$774,217
R01 · FY2023 · HL · contact PI
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$681,286
R01 · FY2023 · HL · contact PI
Center for the Investigation of Factor VIII Inhibitors and Glycosylation$1,323,844
U54 · FY2022 · HL
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia A$774,217
R01 · FY2022 · HL · contact PI
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$685,350
R01 · FY2022 · HL · contact PI
Project 3: Immune regulation by cellular glycosylation for the inhibitory antibody development to factor VIII in hemophilia$489,820
U54 · FY2022 · HL · contact PI
Project-005$270,798
U54 · FY2022 · HL
Project-004$258,200
U54 · FY2022 · HL
Center for the Investigation of Factor VIII Inhibitors and Glycosylation$1,346,699
U54 · FY2021 · HL
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia A$774,401
R01 · FY2021 · HL · contact PI
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$743,605
R01 · FY2021 · HL · contact PI
Project 3: Immune regulation by cellular glycosylation for the inhibitory antibody development to factor VIII in hemophilia$501,976
U54 · FY2021 · HL · contact PI
Project-005$274,914
U54 · FY2021 · HL
Project-004$260,888
U54 · FY2021 · HL
Center for the Investigation of Factor VIII Inhibitors and Glycosylation$1,404,536
U54 · FY2020 · HL
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia A$860,694
R01 · FY2020 · HL · contact PI
Project 3: Immune regulation by cellular glycosylation for the inhibitory antibody development to factor VIII in hemophilia$524,738
U54 · FY2020 · HL · contact PI
Project-005$286,892
U54 · FY2020 · HL
Project-004$271,250
U54 · FY2020 · HL
Center for the Investigation of Factor VIII Inhibitors and Glycosylation$1,384,185
U54 · FY2019 · HL
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$627,844
R01 · FY2019 · HL · contact PI
Project 3: Immune regulation by cellular glycosylation for the inhibitory antibody development to factor VIII in hemophilia$517,351
U54 · FY2019 · HL · contact PI
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia A$482,250
R01 · FY2019 · HL · contact PI
Center for the Investigation of Factor VIII Inhibitors and Glycosylation$1,454,845
U54 · FY2018 · HL
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$627,844
R01 · FY2018 · HL · contact PI
Project 3: Immune regulation by cellular glycosylation for the inhibitory antibody development to factor VIII in hemophilia$549,954
U54 · FY2018 · HL · contact PI
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia A$482,250
R01 · FY2018 · HL · contact PI
Development of clinically feasible Ultrasound-mediated gene therapy for hemophilia$463,181
R01 · FY2018 · HL · contact PI
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$697,736
R01 · FY2017 · HL · contact PI
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia A$482,250
R01 · FY2017 · HL · contact PI
Development of clinically feasible Ultrasound-mediated gene therapy for hemophilia$462,899
R01 · FY2017 · HL · contact PI
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy$663,008
R01 · FY2016 · HL · contact PI
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia A$482,250
R01 · FY2016 · HL · contact PI
Development of clinically feasible Ultrasound-mediated gene therapy for hemophilia$476,946
R01 · FY2016 · HL · contact PI
Development of clinically feasible Ultrasound-mediated gene therapy for hemophilia$515,762
R01 · FY2015 · HL · contact PI
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia A$485,000
R56 · FY2014 · HL · contact PI
In vivo lentiviral transduction of bone marrow cells for hemophilia gene therapy$268,464
R21 · FY2013 · HL · contact PI
Ultrasound-Mediated Gene Therapy for Hemophilia B$809,491
R33 · FY2012 · HL · contact PI
In vivo lentiviral transduction of bone marrow cells for hemophilia gene therapy$235,000
R21 · FY2012 · HL · contact PI
Ultrasound-Mediated Gene Therapy for Hemophilia B$818,532
R33 · FY2011 · HL · contact PI
Nonviral Gene Medicine for Hemophilia A$1,157,090
R01 · FY2010 · HL · contact PI
Ultrasound-Mediated Gene Therapy for Hemophilia B$829,490
R33 · FY2010 · HL · contact PI
Nonviral Gene Medicine for Hemophilia A$1,198,239
R01 · FY2009 · HL · contact PI
Ultrasound-Mediated Gene Therapy for Hemophilia B$435,431
R21 · FY2009 · HL · contact PI
Ultrasound-Mediated Gene Therapy for Hemophilia B$25,978
R21 · FY2009 · HL · contact PI
Ultrasound-Mediated Gene Therapy for Hemophilia B$480,669
R21 · FY2008 · HL · contact PI
Immune Response for Hemophilia After Replacement Therapy$428,045
R01 · FY2008 · HL · contact PI
Immune Response for Hemophilia After Replacement Therapy$428,084
R01 · FY2007 · HL · contact PI
Immune Response for Hemophilia After Replacement Therapy$445,744
R01 · FY2006 · HL · contact PI
Non-viral Gene Medicine for the Treatment of Hemophila$378,394
R01 · FY2006 · HL · contact PI
Immune Response for Hemophilia After Replacement Therapy$485,285
R01 · FY2005 · HL
Non-viral Gene Medicine for the Treatment of Hemophila$387,500
R01 · FY2005 · HL
Non-viral Gene Medicine for the Treatment of Hemophila$387,500
R01 · FY2004 · HL
Non-viral Gene Medicine for the Treatment of Hemophila$273,168
R01 · FY2003 · HL
Non-viral Gene Medicine for the Treatment of Hemophila$105,832
R01 · FY2003 · HL